CRISPR Therapeutics AG (CRSP) Income from Non-Controlling Interests (2015 - 2019)

CRISPR Therapeutics AG (CRSP) has 5 years of Income from Non-Controlling Interests data on file, last reported at $14.2 million in Q1 2019.

• For the quarter ending Q1 2019, Income from Non-Controlling Interests rose 13.6% year-over-year to $14.2 million; the trailing twelve-month figure through Mar 2019 stood at $54.4 million (up 25.93% YoY), and the FY2018 full-year result was $52.5 million, up 45.03% from the prior year.
• Income from Non-Controlling Interests grew to $14.2 million in Q1 2019, from $14.1 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $14.2 million in Q1 2019 to a low of -$16000.0 in Q4 2015.
• A 5-year average of $6.9 million and a median of $9.0 million in 2017 frame the typical range for Income from Non-Controlling Interests.
• Across the five-year window, Income from Non-Controlling Interests tumbled 1300.0% in 2016 and soared 1150100.0% in 2017, its largest moves.
• Tracing CRSP's Income from Non-Controlling Interests over 5 years: stood at -$16000.0 in 2015, then soared by 93.75% to -$1000.0 in 2016, then soared by 1150100.0% to $11.5 million in 2017, then grew by 22.61% to $14.1 million in 2018, then climbed by 0.71% to $14.2 million in 2019.
• Business Quant data shows CRSP's Income from Non-Controlling Interests at $14.2 million in Q1 2019, $14.1 million in Q4 2018, and $12.6 million in Q3 2018.